Hasegawa T - Search Results

1

A case of radio-insensitive SMARCA4-deficient thoracic undifferentiated carcinoma with severe right heart failure.

Ito S, Asahina H, Yamaguchi N, Tomaru U, Hasegawa T, Hatanaka Y, Hatanaka KC, Taguchi H, Harada T, Ohira H, Ikeda D, Mizugaki H, Kikuchi E, Kikuchi J, Sakakibara-Konishi J, Shinagawa N, Konno S. Ito S, et al. Among authors: hasegawa t. Respir Med Case Rep. 2021 Feb 18;32:101364. doi: 10.1016/j.rmcr.2021.101364. eCollection 2021. Respir Med Case Rep. 2021. PMID: 33665078 Free PMC article.

2

Validity and reproducibility of Ki-67 assessment in gastrointestinal stromal tumors and leiomyosarcomas.

Ogino J, Asanuma H, Hatanaka Y, Matsuno Y, Gotoda H, Muraoka S, Tsuji T, Fukazawa Y, Yamashiro K, Kondo N, Iwaki H, Miyokawa N, Hasegawa T. Ogino J, et al. Among authors: hasegawa t. Pathol Int. 2013 Feb;63(2):102-7. doi: 10.1111/pin.12038. Epub 2013 Feb 22. Pathol Int. 2013. PMID: 23464967

3

A typical presentation of primary pulmonary epithelioid sarcoma misdiagnosed as non-small cell lung cancer.

Emori M, Tamakawa M, Kaya M, Takada K, Murase K, Fujita C, Sato S, Takahashi R, Hatanaka KC, Sugita S, Hirano H, Yamashita T, Hasegawa T. Emori M, et al. Among authors: hasegawa t. Pathol Int. 2017 Apr;67(4):222-224. doi: 10.1111/pin.12503. Epub 2017 Jan 12. Pathol Int. 2017. PMID: 28078765 No abstract available.

4

Image analysis is an excellent tool for quantifying Ki-67 to predict the prognosis of gastrointestinal stromal tumor patients.

Sugita S, Hirano H, Hatanaka Y, Fujita H, Kubo T, Kikuchi N, Ito Y, Sugawara T, Segawa K, Hisai H, Yamashita K, Nobuoka T, Matsuno Y, Hasegawa T. Sugita S, et al. Among authors: hasegawa t. Pathol Int. 2018 Jan;68(1):7-11. doi: 10.1111/pin.12611. Epub 2017 Nov 13. Pathol Int. 2018. PMID: 29131458

5

Occult ovarian clear-cell carcinoma diagnosed as primary adenocarcinoma of the lung: A case report of a diagnostic pitfall for clinicians and pathologists.

Kubo T, Hirohashi Y, Fujita H, Sugita S, Kikuchi Y, Shinkawa T, Nakatsugawa M, Tsujiwaki M, Sudo Y, Asai Y, Umeda Y, Takahashi H, Hasegawa T, Torigoe T. Kubo T, et al. Among authors: hasegawa t. Respir Med Case Rep. 2018 Oct 18;25:306-308. doi: 10.1016/j.rmcr.2018.10.013. eCollection 2018. Respir Med Case Rep. 2018. PMID: 30386720 Free PMC article.

6

Usefulness of cell block examination for the cytological diagnosis of thoracic SMARCA4-deficient undifferentiated tumor: A case report.

Minoshima A, Sugita S, Segawa K, Aoyama T, Ito M, Daimon F, Takenami T, Kido T, Moriya J, Nishikiori H, Hasegawa T. Minoshima A, et al. Among authors: hasegawa t. Diagn Cytopathol. 2023 May;51(5):E149-E154. doi: 10.1002/dc.25116. Epub 2023 Feb 11. Diagn Cytopathol. 2023. PMID: 36772934

7

Immunohistochemical expression of PTEN and phosphorylated Akt are not correlated with clinical outcome in breast cancer patients treated with trastuzumab-containing neo-adjuvant chemotherapy.

Yonemori K, Tsuta K, Shimizu C, Hatanaka Y, Hashizume K, Ono M, Kouno T, Ando M, Tamura K, Katsumata N, Hasegawa T, Kinoshita T, Fujiwara Y. Yonemori K, et al. Among authors: hasegawa t. Med Oncol. 2009;26(3):344-9. doi: 10.1007/s12032-008-9127-2. Epub 2008 Nov 18. Med Oncol. 2009. PMID: 19016009

8

Disruption of the blood brain barrier by brain metastases of triple-negative and basal-type breast cancer but not HER2/neu-positive breast cancer.

Yonemori K, Tsuta K, Ono M, Shimizu C, Hirakawa A, Hasegawa T, Hatanaka Y, Narita Y, Shibui S, Fujiwara Y. Yonemori K, et al. Among authors: hasegawa t. Cancer. 2010 Jan 15;116(2):302-8. doi: 10.1002/cncr.24735. Cancer. 2010. PMID: 19937674 Free article.

9

Immunohistochemical expression of HER1, HER3, and HER4 in HER2-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy.

Yonemori K, Tsuta K, Shimizu C, Hatanaka Y, Hirakawa A, Ono M, Kouno T, Katsumata N, Ando M, Tamura K, Hasegawa T, Kinoshita T, Fujiwara Y. Yonemori K, et al. Among authors: hasegawa t. J Surg Oncol. 2010 Mar 1;101(3):222-7. doi: 10.1002/jso.21486. J Surg Oncol. 2010. PMID: 20087905

10

Contrasting prognostic implications of platelet-derived growth factor receptor-β and vascular endothelial growth factor receptor-2 in patients with angiosarcoma.

Yonemori K, Tsuta K, Ando M, Hirakawa A, Hatanaka Y, Matsuno Y, Chuman H, Yamazaki N, Fujiwara Y, Hasegawa T. Yonemori K, et al. Among authors: hasegawa t. Ann Surg Oncol. 2011 Oct;18(10):2841-50. doi: 10.1245/s10434-011-1640-4. Epub 2011 Mar 16. Ann Surg Oncol. 2011. PMID: 21409488

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

6,321 results

Search Page